Mirjam Keßler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mirjam Keßler has a total of 478 co-authors. Here are the top co-authors by number of shared publications:
Wolfgang Rottbauer
24 shared publications- Wolfgang Rottbauer
Ulm University Heart Center
14 shared publications - Dominik Felbel
Ulm University Heart Center
10 shared publications - Lukas Stolz
Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU München, Munich, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany
10 shared publications - Matthias Gröger
Department of Cardiology, University Heart Center Ulm , Albert-Eistein-Allee 23, Ulm 89081
10 shared publications - Volker Rudolph
Department of General and Interventional Cardiology/Angiology, Heart- and Diabetes Center NRW, Ruhr-Universität-Bochum, Bad Oeynhausen, Germany
10 shared publications
Latest Publications
- 12 November 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
Effects of Transcatheter Tricuspid Edge‐to‐Edge Repair on Right Heart Dimension and Function
Background: Transcatheter tricuspid edge‐to‐edge repair (T‐TEER) has developed as a treatment option for patients experiencing severe tricuspid regurgitation. T‐TEER consistently reduces tricuspid regurgitation, but data on subsequent right heart remodeling remain limited. The aim of this study was to evaluate changes in right heart dimension and function after T‐TEER using extended echocardiographic follow‐up. Methods: The study was based on the international EuroTR (European Registry of Transcatheter Repair for Tricuspid Regurgitation), including patients undergoing T‐TEER between 2016 and 2024 at 18 European centers. Eligible were patients with available baseline and follow‐up (≥90 days postprocedure) echocardiographic assessment. Results: A total of 699 patients (mean age, 78±8 years; 56% women) were included in the analysis. Echocardiographic follow‐up was performed at a median of 407 days (interquartile range, 205–801 days). Right heart dimensions significantly decreased: right ventricular (RV) midventricular diameter from 40.2±8.9 to 37.1±8.4 mm ( P 2 ( P P P <0.001) was observed. Conclusions: In the subset of surviving patients with available echocardiographic follow‐up, treatment with T‐TEER led to favorable long‐term changes with reduced RV dimension, associated with procedural success. RV function modestly decreased, likely reflecting normalization after volume unloading.
- 12 November 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
Effects of Transcatheter Tricuspid Edge‐to‐Edge Repair on Right Heart Dimension and Function
Background: Transcatheter tricuspid edge‐to‐edge repair (T‐TEER) has developed as a treatment option for patients experiencing severe tricuspid regurgitation. T‐TEER consistently reduces tricuspid regurgitation, but data on subsequent right heart remodeling remain limited. The aim of this study was to evaluate changes in right heart dimension and function after T‐TEER using extended echocardiographic follow‐up. Methods: The study was based on the international EuroTR (European Registry of Transcatheter Repair for Tricuspid Regurgitation), including patients undergoing T‐TEER between 2016 and 2024 at 18 European centers. Eligible were patients with available baseline and follow‐up (≥90 days postprocedure) echocardiographic assessment. Results: A total of 699 patients (mean age, 78±8 years; 56% women) were included in the analysis. Echocardiographic follow‐up was performed at a median of 407 days (interquartile range, 205–801 days). Right heart dimensions significantly decreased: right ventricular (RV) midventricular diameter from 40.2±8.9 to 37.1±8.4 mm ( P 2 ( P P P <0.001) was observed. Conclusions: In the subset of surviving patients with available echocardiographic follow‐up, treatment with T‐TEER led to favorable long‐term changes with reduced RV dimension, associated with procedural success. RV function modestly decreased, likely reflecting normalization after volume unloading.
- Open Access
- 2 November 2026
- Published by Elsevier in JACC: Advances
Prognostic Value of TVARC-Based Right Ventricular Dysfunction Grading in Tricuspid Transcatheter Edge-to-Edge Repair
- 2 November 2026
- Published by Elsevier in JACC: Advances
Open AccessPrognostic Value of TVARC-Based Right Ventricular Dysfunction Grading in Tricuspid Transcatheter Edge-to-Edge Repair
- 11 September 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
Impact of Tricuspid Regurgitation on Outcomes After Transcatheter Edge-to-Edge Repair for Primary Mitral Regurgitation: The PRIME-MR Registry
BACKGROUND: The presence of tricuspid regurgitation (TR) may affect prognosis in patients with primary mitral regurgitation. This study sought to investigate the impact of concomitant TR on clinical outcomes in patients with primary mitral regurgitation undergoing mitral transcatheter edge-to-edge repair (M-TEER). METHODS: The PRIME-MR registry (Outcomes of Patients Treated With Mitral Transcatheter Edge-to-edge Repair for Primary Mitral Regurgitation) included 3083 patients with severe primary mitral regurgitation undergoing M-TEER from 2008 to 2022 at 25 international sites. Only patients with successful M-TEER procedures (mitral regurgitation≤Moderate) were analyzed. The study population was stratified by baseline TR severity: TR≤Moderate (TR≤Mod) versus TR≥Severe (TR≥Sev). The primary end point was 2-year all-cause mortality. RESULTS: A total of 2155 patients were analyzed: TR≥Sev (n=421 [20%]) versus TR≤Mod (n=1734 [80%]). Patients with TR≥Sev were more likely to be New York Heart Association III/IV ( P =0.003), have shorter 6-minute walk distance ( P P P P P P P log-rank P Gray =0.018) than TR≤Mod. Baseline TR≥Sev was an independent predictor of 2-year mortality (adjusted hazard ratio, 2.01 [95% CI, 1.35–3.00]; P P log-rank =0.0037) than TR≤Mod. CONCLUSIONS: In the PRIME-MR registry, 20% of patients with primary mitral regurgitation had severe TR at baseline. TR severity improved in 30% of TR≥Sev patients after successful M-TEER. The presence of TR≥Sev was independently associated with increased all-cause mortality at 2 years.
- 11 September 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
Impact of Tricuspid Regurgitation on Outcomes After Transcatheter Edge-to-Edge Repair for Primary Mitral Regurgitation: The PRIME-MR Registry
BACKGROUND: The presence of tricuspid regurgitation (TR) may affect prognosis in patients with primary mitral regurgitation. This study sought to investigate the impact of concomitant TR on clinical outcomes in patients with primary mitral regurgitation undergoing mitral transcatheter edge-to-edge repair (M-TEER). METHODS: The PRIME-MR registry (Outcomes of Patients Treated With Mitral Transcatheter Edge-to-edge Repair for Primary Mitral Regurgitation) included 3083 patients with severe primary mitral regurgitation undergoing M-TEER from 2008 to 2022 at 25 international sites. Only patients with successful M-TEER procedures (mitral regurgitation≤Moderate) were analyzed. The study population was stratified by baseline TR severity: TR≤Moderate (TR≤Mod) versus TR≥Severe (TR≥Sev). The primary end point was 2-year all-cause mortality. RESULTS: A total of 2155 patients were analyzed: TR≥Sev (n=421 [20%]) versus TR≤Mod (n=1734 [80%]). Patients with TR≥Sev were more likely to be New York Heart Association III/IV ( P =0.003), have shorter 6-minute walk distance ( P P P P P P P log-rank P Gray =0.018) than TR≤Mod. Baseline TR≥Sev was an independent predictor of 2-year mortality (adjusted hazard ratio, 2.01 [95% CI, 1.35–3.00]; P P log-rank =0.0037) than TR≤Mod. CONCLUSIONS: In the PRIME-MR registry, 20% of patients with primary mitral regurgitation had severe TR at baseline. TR severity improved in 30% of TR≥Sev patients after successful M-TEER. The presence of TR≥Sev was independently associated with increased all-cause mortality at 2 years.
- Open Access
- 17 August 2026
- Published by Taylor & Francis in Future Cardiology
- Vol. 22 (9) , 911-916
Interventional treatment options for elderly patients with mitral regurgitation
1. The prevalence of mitral regurgitation (MR) increases with age and is reported to be about 7% for moderate-to-severe MR in nonagenerians compared with <2% in those under 60 years [1,2]. Simultan...
- 17 August 2026
- Published by Taylor & Francis in Future Cardiology
- Vol. 22 (9) , 911-916
Open AccessInterventional treatment options for elderly patients with mitral regurgitation
1. The prevalence of mitral regurgitation (MR) increases with age and is reported to be about 7% for moderate-to-severe MR in nonagenerians compared with <2% in those under 60 years [1,2]. Simultan...
- Open Access
- 10 August 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (15) , 2140-2142
Acute Intraprocedural Mitral Annuloplasty During Transcatheter Mitral Valve Replacement With a Novel Valve-in-Ring System
- 10 August 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (15) , 2140-2142
Open AccessAcute Intraprocedural Mitral Annuloplasty During Transcatheter Mitral Valve Replacement With a Novel Valve-in-Ring System
- Open Access
- 22 July 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (8) , 103033
Transcatheter Tricuspid Valve Annuloplasty vs Edge-to-Edge Repair
- 22 July 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (8) , 103033
Open AccessTranscatheter Tricuspid Valve Annuloplasty vs Edge-to-Edge Repair
- Open Access
- 20 May 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (15) , 2080-2094
Clinical Outcomes of Transfemoral Transcatheter Mitral Valve Replacement: Results from the CHOICE-MI Registry
- 20 May 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (15) , 2080-2094
Open AccessClinical Outcomes of Transfemoral Transcatheter Mitral Valve Replacement: Results from the CHOICE-MI Registry
- Open Access
- 14 May 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (6) , 102782
Sex-Specific Outcomes in Patients Undergoing Mitral Valve Transcatheter Edge-to-Edge Repair
- 14 May 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (6) , 102782
Open AccessSex-Specific Outcomes in Patients Undergoing Mitral Valve Transcatheter Edge-to-Edge Repair
- Open Access
- 11 May 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (9) , 1155-1157
2-Year Outcomes Following Transseptal Mitral Valve Replacement With the HighLife System
- 11 May 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (9) , 1155-1157
Open Access2-Year Outcomes Following Transseptal Mitral Valve Replacement With the HighLife System
- Open Access
- 16 March 2026
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 13 (3)
Left ventricular reverse remodelling after mitral transcatheter edge-to-edge repair: results from the EXPANDed studies
Background and Aims: Left ventricular reverse remodelling (LVRR) is a key objective of contemporary heart failure (HF) therapies and is characterized by reversal of left ventricular (LV) dilation and dysfunction. Objectives: To report the incidence and clinical impact of early (30-day) LVRR patients with primary (PMR) and secondary mitral regurgitation (SMR) treated with mitral transcatheter edge-to-edge repair (M-TEER), and to identify independent associations with early LVRR. Methods: The EXPANDed cohort includes 2205 patients treated with M-TEER from the EXPAND and EXPAND G4 studies. Patients were classified as having early LVRR if they demonstrated a >10% reduction in LV dimension or volume from baseline to 30 days. All LV measurements were assessed by independent echocardiographic core laboratories. Results: Among 527 SMR patients, 338 patients (64.1%) experienced early LVRR after M-TEER. At 1 year, SMR patients with early LVRR had significantly lower rates of death or HF hospitalizations compared with those without (early LVRR: 24.7% vs no early LVRR: 35.9%, P = .009), despite similar MR reduction (MR mild or less ≥93% in both groups) and comparable improvements in functional status (NYHA ≤II ≥78%) and quality of life (∼20-points improvement per KCCQ-OS). Independent associations with early LVRR included hypertension [odds ratio (OR) = 1.96, P = .004], absence of prior cardiac surgeries (OR = 0.51, P = .002), and smaller LV end-systolic volume (OR = 0.81, P = .002). Among 536 PMR patients, 391 (73.0%) experienced early LVRR at 30 days. At 1 year, PMR patients with early LVRR group had similar clinical (composite all-cause mortality or HF hospitalization: early LVRR: 14.5% vs no early LVRR: 17.1%, P = .47) and symptomatic outcomes (≥83% NYHA ≤II; ∼19-point improvement per KCCQ-OS) compared with those without. However, among PMR patients with dilated ventricles, early LVRR group was associated with significantly lower all-cause mortality (early LVRR: 3.8%, no Early LVRR: 14.0%, P = .028). Conclusions: Regardless of aetiology, most patients experienced early LVRR after M-TEER with significant MR reduction and symptom relief. In SMR patients, early LVRR was associated with lower rates of HF hospitalization and death.
- 16 March 2026
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 13 (3)
Open AccessLeft ventricular reverse remodelling after mitral transcatheter edge-to-edge repair: results from the EXPANDed studies
Background and Aims: Left ventricular reverse remodelling (LVRR) is a key objective of contemporary heart failure (HF) therapies and is characterized by reversal of left ventricular (LV) dilation and dysfunction. Objectives: To report the incidence and clinical impact of early (30-day) LVRR patients with primary (PMR) and secondary mitral regurgitation (SMR) treated with mitral transcatheter edge-to-edge repair (M-TEER), and to identify independent associations with early LVRR. Methods: The EXPANDed cohort includes 2205 patients treated with M-TEER from the EXPAND and EXPAND G4 studies. Patients were classified as having early LVRR if they demonstrated a >10% reduction in LV dimension or volume from baseline to 30 days. All LV measurements were assessed by independent echocardiographic core laboratories. Results: Among 527 SMR patients, 338 patients (64.1%) experienced early LVRR after M-TEER. At 1 year, SMR patients with early LVRR had significantly lower rates of death or HF hospitalizations compared with those without (early LVRR: 24.7% vs no early LVRR: 35.9%, P = .009), despite similar MR reduction (MR mild or less ≥93% in both groups) and comparable improvements in functional status (NYHA ≤II ≥78%) and quality of life (∼20-points improvement per KCCQ-OS). Independent associations with early LVRR included hypertension [odds ratio (OR) = 1.96, P = .004], absence of prior cardiac surgeries (OR = 0.51, P = .002), and smaller LV end-systolic volume (OR = 0.81, P = .002). Among 536 PMR patients, 391 (73.0%) experienced early LVRR at 30 days. At 1 year, PMR patients with early LVRR group had similar clinical (composite all-cause mortality or HF hospitalization: early LVRR: 14.5% vs no early LVRR: 17.1%, P = .47) and symptomatic outcomes (≥83% NYHA ≤II; ∼19-point improvement per KCCQ-OS) compared with those without. However, among PMR patients with dilated ventricles, early LVRR group was associated with significantly lower all-cause mortality (early LVRR: 3.8%, no Early LVRR: 14.0%, P = .028). Conclusions: Regardless of aetiology, most patients experienced early LVRR after M-TEER with significant MR reduction and symptom relief. In SMR patients, early LVRR was associated with lower rates of HF hospitalization and death.